{
    "url_original": "https://www.wsj.com/articles/gilead-to-pay-1-4-billion-for-hepatitis-drug-maker-myr-gmbh-of-germany-11607605200?mod=business_lead_pos7",
    "url": "gilead-to-pay-1-4-billion-for-hepatitis-drug-maker-myr-gmbh-of-germany-11607605200",
    "title": "Gilead to Pay $1.4 Billion for Hepatitis Drugmaker MYR GmbH of Germany",
    "sub_head": "All-cash deal will deepen Gilead’s portfolio of hepatitis treatments and marks company’s latest acquisition to increase revenue growth",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-271178?width=620&size=1.5",
    "image_1": "im-271178.jpg",
    "time": "2020-12-10 08:00:00",
    "body": "Gilead Sciences Inc.  said Thursday it will acquire Germany’s MYR GmbH and its new hepatitis drug for about $1.4 billion, reported as 1.15 billion euros, in the company’s latest deal to jump-start revenue growth.<br />The all-cash deal, expected to close in the first quarter, will expand Gilead’s offerings of hepatitis treatments.<br />MYR, a 35-person company based in Bad Homburg, received conditional approval from European regulators in July to market its drug Hepcludex for treatment of hepatitis D, a viral disease that can lead to liver cirrhosis, cancer and death.<br />The disease affects at least 12 million people globally and about 230,000 in the U.S. and Europe, Gilead said. MYR is currently selling the drug in France, Germany and Austria and plans to launch in more countries next year, Gilead said. The company intends to seek U.S. approval in the second half of 2021.<br />Under the terms of the deal, Gilead will pay MYR shareholders up to $362 million, reported as 300 million euros, in additional milestone payments upon a U.S. approval, Gilead said."
}